CD274 and neuroendocrine neoplasm: In addition, a combination of AZD2811NP and durvalumab, a PD-L1 inhibitor, is currently being tested in a phase II clinical trial (NCT04745689) for extensive stage small cell lung cancer, another neuroendocrine tumor.